United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents.   methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin’s lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. methotrexate is indicated in the symptomatic control of se

United States - English - NLM (National Library of Medicine)

sandoz inc - methotrexate sodium (unii: 3ig1e710zn) (methotrexate - unii:yl5fz2y5u1) - methotrexate 25 mg in 1 ml - methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. in acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. methotrexate is also indicated in the treatment of meningeal leukemia. methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous t cell lymphoma), and lung cancer, particularly squamous cell and small cell types. methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-hodgkin's lymphomas. methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - azathioprine, quantity: 50 mg - injection, powder for - excipient ingredients: sodium hydroxide - indications as at 11 february 2005: imuran is used as an immunosuppressant antimetabolite either alone, or more commonly, in combination with other agents (usually corticosteroids) and procedures which influence the immune response. therapeutic effect may be evident only after weeks or months and can include a steroid-sparing effect, thereby reducing the toxicity associated with high dosage and prolonged usage of corticosteroids. imuran, in combination with corticosteroids and/or other immunosuppressive agents and procedures, is indicated in the management of patients receiving organ transplants. imuran, either alone or more usually in combination with corticosteroids and/or other procedures, has been used with clinical benefit which may include reduction of dosage or discontinuation of corticosteroids, in a proportion of patients suffering form the following: severe rheumatoid arthritis; systemic lupus erythematosus; dermatomyositis/polymyositis; autoimmune chronic active hepatitis; pemphigus vulgaris; polya

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - aciclovir 500mg - powder for infusion - 500 mg - active: aciclovir 500mg excipient: sodium hydroxide

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 500mg;   - powder for injection - 500 mg - active: flucloxacillin sodium monohydrate 500mg  

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - methylprednisolone sodium succinate 663mg equivalent to 500 mg methylprednisolone;   - powder for injection - 500 mg - active: methylprednisolone sodium succinate 663mg equivalent to 500 mg methylprednisolone   excipient: dibasic sodium phosphate monobasic sodium phosphate

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - sodium valproate - powder and solvent for solution for injection/infusion - 400 milligram(s) - fatty acid derivatives; valproic acid

Malta - English - Medicines Authority

medochemie limited 1-10 constantinoupleos street, 3011 limassol, cyprus - amoxicillin - powder for solution for injection/infusion - amoxicillin 500 mg - antibacterials for systemic use

Australia - English - Department of Health (Therapeutic Goods Administration)

celltrion healthcare australia pty ltd - infliximab, quantity: 100 mg - injection, powder for - excipient ingredients: sucrose; monobasic sodium phosphate monohydrate; dibasic sodium phosphate dihydrate; polysorbate 80 - rheumatoid arthritis in adults,remsima, in combination with methotrexate, is indicated for the reduction of signs and symptoms and prevention of structural joint damage (erosions and joint space narrowing) in:,- patients with active disease despite treatment with methotrexate,- patients with active disease who have not previously received methotrexate.,remsima should be given in combination with methotrexate. efficacy and safety in rheumatoid arthritis have been demonstrated only in combination with methotrexate.,ankylosing spondylitis,remsima is indicated for the reduction of signs and symptoms and improvement in physical function in patients with active disease.,psoriatic arthritis,remsima is indicated for the treatment of the signs and symptoms, as well as for the improvement in physical function in adult patients with active and progressive psoriatic arthritis who have responded inadequately to disease-modifying anti-rheumatic drug (dmard) therapy. remsima may be administered in combination with methotrexate.,psoriasis,remsima is indicated for the treatment of adult patients with moderate to severe plaque psoriasis for whom phototherapy or conventional systemic treatments have been inadequate or are inappropriate. safety and efficacy beyond 12 months have not been established.,crohn?s disease in adults and in children and adolescents (6 to 17 years),remsima is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms and to induce and maintain clinical remission in patients who have an inadequate response to conventional therapies.,refractory fistulising crohn?s disease,remsima is indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients.,ulcerative colitis in adults and in children and adolescents (6 to 17 years),remsima is indicated for the treatment of moderately severe to severe active ulcerative colitis in patients who have had an inadequate response to conventional therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - esomeprazole sodium, quantity: 42.6 mg (equivalent: esomeprazole, qty 40 mg) - injection, powder for - excipient ingredients: disodium edetate; sodium hydroxide - ? the short-term management of gastro-oesophageal reflux disease (gord) in patients with oesophagitis and/or severe symptoms of reflux as an alternative when oral therapy is inappropriate. ? prevention of rebleeding in patients following therapeutic endoscopy for acute, bleeding gastric or duodenal ulcers. ? short-term management in patients requiring continued non-steroidal anti- inflammatory drug (nsaid) therapy when oral therapy is inappropriate: ? healing of gastric ulcers associated with nsaid therapy ? prevention of gastric and duodenal ulcers associated with nsaid therapy, in patients at risk ? esomeprazole sun should be replaced with oral therapy as soon as practicable.